CA2624676A1 - Tyrosine kinase inhibitors - Google Patents

Tyrosine kinase inhibitors Download PDF

Info

Publication number
CA2624676A1
CA2624676A1 CA002624676A CA2624676A CA2624676A1 CA 2624676 A1 CA2624676 A1 CA 2624676A1 CA 002624676 A CA002624676 A CA 002624676A CA 2624676 A CA2624676 A CA 2624676A CA 2624676 A1 CA2624676 A1 CA 2624676A1
Authority
CA
Canada
Prior art keywords
alkyl
aryl
cycloalkyl
alkenyl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002624676A
Other languages
English (en)
French (fr)
Inventor
Jongwon Lim
Ana Esther Gabarda Ortega
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2624676A1 publication Critical patent/CA2624676A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA002624676A 2005-10-21 2006-10-18 Tyrosine kinase inhibitors Abandoned CA2624676A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72899705P 2005-10-21 2005-10-21
US60/728,997 2005-10-21
PCT/US2006/040664 WO2007050380A2 (en) 2005-10-21 2006-10-18 Tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
CA2624676A1 true CA2624676A1 (en) 2007-05-03

Family

ID=37968376

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002624676A Abandoned CA2624676A1 (en) 2005-10-21 2006-10-18 Tyrosine kinase inhibitors

Country Status (6)

Country Link
US (1) US7790739B2 (enExample)
EP (1) EP1951047A2 (enExample)
JP (1) JP2009512706A (enExample)
AU (1) AU2006306496A1 (enExample)
CA (1) CA2624676A1 (enExample)
WO (1) WO2007050380A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE524445T1 (de) 2005-06-23 2011-09-15 Merck Sharp & Dohme Benzocycloheptapyridine als inhibitoren der tyrosinkinase met
US7893081B2 (en) 2007-12-20 2011-02-22 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2011039527A1 (en) * 2009-09-30 2011-04-07 Merck Sharp & Dohme Ltd Formulations for c-met kinase inhibitors
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
EP3444242A3 (en) 2009-11-05 2019-03-20 Rhizen Pharmaceuticals S.A. Novel benzopyran kinase modulators
PT2705029T (pt) 2011-05-04 2019-02-01 Rhizen Pharmaceuticals S A Novos compostos como moduladores de proteína quinases
HRP20171610T1 (hr) 2012-07-04 2018-03-23 Rhizen Pharmaceuticals S.A. Selektivni inhibitori pi3k delta
WO2016089830A1 (en) 2014-12-05 2016-06-09 Merck Sharp & Dohme Corp. Novel tricyclic compounds as inhibitors of mutant idh enzymes
EP3226690B1 (en) 2014-12-05 2020-05-20 Merck Sharp & Dohme Corp. Novel tricyclic compounds as inhibitors of mutant idh enzymes
US10442819B2 (en) 2014-12-05 2019-10-15 Merck Sharp & Dohme Corp. Tricyclic compounds as inhibitors of mutant IDH enzymes
CN116410211A (zh) * 2021-12-29 2023-07-11 山东新时代药业有限公司 一种苯并呋喃类化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826853A (en) 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
EP0798288B1 (en) * 1995-10-16 2001-05-16 Kyowa Hakko Kogyo Co., Ltd. Triciclic compounds
ES2286275T3 (es) * 2001-09-19 2007-12-01 Pharmacia Corporation Compuestos de pirazolo sustituidos para el tratamiento de la inflamacion.
AU2003230758A1 (en) 2002-04-02 2003-10-20 Merck And Co., Inc. 5h-benzo(4,5)cyclohepta(1,2-b)pyridine nmda/nr2b antagonists
ATE524445T1 (de) 2005-06-23 2011-09-15 Merck Sharp & Dohme Benzocycloheptapyridine als inhibitoren der tyrosinkinase met
US20090291941A1 (en) 2005-10-21 2009-11-26 Dinsmore Christopher J Tyrosine Kinase Inhibitors
AU2006306499A1 (en) 2005-10-21 2007-05-03 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors

Also Published As

Publication number Publication date
AU2006306496A1 (en) 2007-05-03
JP2009512706A (ja) 2009-03-26
EP1951047A2 (en) 2008-08-06
US20090247565A1 (en) 2009-10-01
WO2007050380A2 (en) 2007-05-03
US7790739B2 (en) 2010-09-07
WO2007050380A3 (en) 2007-07-12

Similar Documents

Publication Publication Date Title
US20090156617A1 (en) Tyrosine kinase inhibitors
US8222269B2 (en) Tyrosine kinase inhibitors
EP1896421B1 (en) Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met
US20100267707A1 (en) Tyrosine Kinase Inhibitors
AU2007210061A1 (en) Inhibitors of fatty acid synthase (FAS)
CA2673410A1 (en) Pyrrolo [3, 2-a] pyridine derivatives for inhibiting ksp kinesin activity
CA2595127A1 (en) Mitotic kinesin inhibitors
US20090149467A1 (en) Tyrosine Kinase Inhibitors
US7790739B2 (en) Tyrosine kinase inhibitors
US20090131423A1 (en) Tyrosine Kinase Inhibitors
US20090291941A1 (en) Tyrosine Kinase Inhibitors
CA2809178A1 (en) Tyrosine kinase inhibitors

Legal Events

Date Code Title Description
FZDE Discontinued